Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Background Peripheral blood hematopoietic cell transplantation ( PBHCT ) is a feasible treatment option for dogs with B‐cell lymphoma. Objective To examine apheresis and PBHCT outcomes in dogs diagnosed with T‐cell lymphoma ( TCL ). Animals Fifteen client‐owned dogs diagnosed with high‐grade TCL . Methods After high‐dose cyclophosphamide and rhG‐colony‐stimulating (rhG‐ CSF ) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation ( TBI ). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. Results More than 2 × 10 6 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B‐cell lymphoma 120 days post‐ PBHCT . The median disease‐free interval and overall survival ( OS ) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS . Two of 13 (15%) dogs were alive 741 and 772 days post‐ PBHCT . Conclusions and Clinical Importance PBHCT may be considered as a treatment option for dogs with TCL .